Abstract
The effectiveness of five different serotonin antagonists in the prevention of migraine was compared in 290 patients followed for periods of up to three years. Methysergide 3-6 mg. daily was most effective, with 20% of treated patients becoming headache-free and a further 44% remaining more than “half improved.” The corresponding figures for BC105 were 10% and 40%, respectively.
The results with BC105 were significantly better than those with placebo (P<0·02). The total improvement rates with methdilazine (45%) and cyproheptadine (43%) were better than those with placebo (32%) but did not achieve statistical significance. A new preparation, methylergol carbamide maleate, which is chemically related to methysergide, did not give better results than placebo.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anthony M., Hinterberger H., Lance J. W. Plasma serotonin in migraine and stress. Arch Neurol. 1967 May;16(5):544–552. doi: 10.1001/archneur.1967.00470230096013. [DOI] [PubMed] [Google Scholar]
- Anthony M., Lance J. W. Indomethacin in migraine. Med J Aust. 1968 Jan 13;1(2):56–57. doi: 10.5694/j.1326-5377.1968.tb27465.x. [DOI] [PubMed] [Google Scholar]
- Bianchine J. R., Eade N. R. The effect of 5-hydroxytryptamine on the cotton pellet local inflammatory response in the rat. J Exp Med. 1967 Mar 1;125(3):501–510. doi: 10.1084/jem.125.3.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
- CURRAN D. A., LANCE J. W. CLINICAL TRIAL OF METHYSERGIDE AND OTHER PREPARATIONS IN THE MANAGEMENT OF MIGRAINE. J Neurol Neurosurg Psychiatry. 1964 Oct;27:463–469. doi: 10.1136/jnnp.27.5.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Curran D. A., Hinterberger H., Lance J. W. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain. 1965 Dec;88(5):997–1010. doi: 10.1093/brain/88.5.997. [DOI] [PubMed] [Google Scholar]
- DALESSIO D. J., CAMP W. A., GOODELL H., WOLFF H. G. Studies on headache. The mode of action of UML-491 and its relevance to the nature of vascular headache of the migraine type. Arch Neurol. 1961 Mar;4:235–240. doi: 10.1001/archneur.1961.00450090001001. [DOI] [PubMed] [Google Scholar]
- Feher P. J., Kalz F. Studies in vascular permeability of human skin bradykinin. Dermatologica. 1966;133(3):190–204. doi: 10.1159/000254328. [DOI] [PubMed] [Google Scholar]
- Lance J. W., Anthony M. Clinical trial of a new serotonin antagonist, BC105, in the prevention of migraine. Med J Aust. 1968 Jan 13;1(2):54–55. doi: 10.5694/j.1326-5377.1968.tb27464.x. [DOI] [PubMed] [Google Scholar]
- Lance J. W., Anthony M., Gonski A. Serotonin, the carotid body, and cranial vessels in migraine. Arch Neurol. 1967 May;16(5):553–558. doi: 10.1001/archneur.1967.00470230105014. [DOI] [PubMed] [Google Scholar]
- MILLER J., FISHMAN A. A serotonin antagonist in the treatment of allergic and allied disorders. Ann Allergy. 1961 Feb;19:164–171. [PubMed] [Google Scholar]
- Ryan R. E. Double-blind crossover comparison of bc-105, methysergide and placebo in the prophylaxis of migraine headache. Headache. 1968 Oct;8(3):118–126. doi: 10.1111/j.1526-4610.1968.hed0803118.x. [DOI] [PubMed] [Google Scholar]
- SICUTERI F. Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine. Int Arch Allergy Appl Immunol. 1959;15:300–307. doi: 10.1159/000229055. [DOI] [PubMed] [Google Scholar]
- Sicuteri F., Franchi G., Del Bianco P. L. An antaminic drug, BC 105, in the prophylaxis of migraine. Pharmacological, clinical, and therapeutic experiences. Int Arch Allergy Appl Immunol. 1967;31(1):78–93. doi: 10.1159/000229856. [DOI] [PubMed] [Google Scholar]